ALNY News and Press, Alnylam Pharmaceuticals Inc. From 01/22/23

Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperformed in the fourth quarter, dr...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...

Summary iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. Healthcare and pharmaceutical shares have a strong track record of holding up during bear markets and recessions over the last 100 years. The Top 10 hold...

Summary Alnylam's fourth quarter product revenue was more or less as expected, with a faster/better-than-expected pace of switching between Onpattro and Amvuttra and further patient growth in Oxlumo and Givlaari. Investors will have multiple clinical read-outs to anticipate this year, i...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) said preliminary full year global net product revenues for its drugs Onpattro, Amvuttra, Givlaari and Oxlumo amounted to $894M, growing +35% Y/Y (+43% Y/Y at constant exchange rate). Onpattro (patisiran) and Amvuttra (vu...

– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO ® , AMVUTTRA ® , GIVLAARI ® , and OXLUMO ® , Representing 35% Annual Growth (43% Using Constant Exchange Rate**) – – Strength of ...

Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...

Summary Today, I explain why I've taken a position in VIR, including going over its pipeline, partners, and anticipated milestones. I then look at the company's valuation and cash position as well as Seeking Alpha's quant ratings. After considering the risks, I think this is one of ...

Alnylam Pharmaceuticals ( NASDAQ: ALNY ) on Thursday said lead independent director Amy Schulman will assume the role of chair of the board from Michael Bonney. Bonney will continue on the board as a non-independent director. Bonney had been serving an interim role ...